ERBB2 and breast carcinoma: For HER2 breast cancer subtype, Pharmacologic FASN inhibitors were found to suppress p185(HER2) oncoprotein expression and tyrosine kinase activity in breast cancer overexpressing HER2 [43], which shows the correlation between FASN and HER2 type breast cancer.